Home > Blog > Research > Equity Research: Sanofi
On October 28, 2021, Sanofi reported robust financial third quarter results for 2021. The pharmaceutical company reported double-digit sales growth of 10.1% during the third quarter, which predominantly were driven by the notable performance of Dupixent, record sales of Vaccines and continued strong business momentum in Consumer Healthcare. Notably, these results are in line with the direction provided by the company in the previous quarter. In addition, exchange rate movements had a neutral effect in the third quarter, the negative impact of the U.S. dollar, Japanese yen and Turkish lira was offset by the increase of the Chinese Yuan and some other currencies. In specific terms, revenue in the first nine months of 2021 amounted to €27.8 billion on a reported basis. Click here to access the report

Disclaimer

The information provided on this website is being provided solely for educational and informational purposes and should not be construed as investment advice, advice concerning particular investments or investment decisions, or tax or legal advice. Similarly, any views or opinions expressed on this website are not intended and should not be construed as being investment, tax or legal advice or recommendations. Investment advice should always be based on the particular circumstances of the person to whom it is directed, which circumstances have not been taken into consideration by the persons expressing the views or opinions appearing on this website. Calamatta Cuschieri Investment Services Ltd has not verified and consequently neither warrants the accuracy nor the veracity of any information, views, or opinions appearing on this website. You should always take professional investment advice in connection with, or independently research and verify, any information that you find or views or opinions which you read on our website and wish to rely upon, whether for the purpose of making an investment decision or otherwise. CC does not accept liability for losses suffered by persons as a result of information, views, or opinions appearing on this website.

Calamatta Cuschieri Investment Services Ltd is licensed to conduct investment services business under the Investments Services Act by the MFSA and is also registered as a Tied Insurance Intermediary under the Insurance Distribution Act.